# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
https://news.bloomberglaw.com/health-law-and-business/ozempic-may-lower-risk-of-obesity-related-cancers-study-finds
https://www.usatoday.com/story/opinion/2024/07/02/biden-sanders-prescription-drug-cost-ozempic-wegovy/74232827007/
Hunterbrook releases a bearish report alleging that Hims & Hers sells knockoff GLP-1 weight loss drugs and relies on a sing...
Jefferies analyst Glen Santangelo maintains Hims & Hers Health (NYSE:HIMS) with a Hold and raises the price target from ...
NVDAMUTSLAHIMSBBAIRIVNAAPLWAYWBAData from https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment
https://hntrbrk.com/hims/